Dark pool trades occurred in Royalty Pharma $RPRX stock from October 25 – 28, 2002. The dark pool trading appears to be buying because of how $RPRX stock rose following the prints being made public.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. The compnay’s portfolio includes royalties on commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta and Vertex’s Kalydeco, Symdeko and Trikafta, and development-stage product candidates.
- Dark Pool Trading in Royalty Pharma $RPRX Stock
- Bullish Option Flow Occurred On October 24, 2022
- Royalty Pharma Declares Fourth Quarter 2022 Dividend
- Royalty Pharma enters schizophrenia R&D funding collaboration with Merck
- Jim Cramer: Newly public Royalty Pharma is a great way to play biotech
- Royalty Pharma $RPRX Stock Technical Analysis
Dark Pool Trading in Royalty Pharma $RPRX Stock
Royalty Pharma will announce third quarter 2022 financial results on November 8, 2022, before the U.S. financial markets open. Could the dark pool orders be institutional investors front-running the upcoming Q3 financial results?
Bullish Option Flow Occurred On October 24, 2022
Bullish option flow was detected in $RPRX stock on October 24, 2022. Open interest is rising in the $45 call option contract that expires on January 20, 2023, which favors the Bulls.
Royalty Pharma Declares Fourth Quarter 2022 Dividend
On October 17, 2022, the board of directors of Royalty Pharma plc $RPRX approved the payment of a dividend for the fourth quarter of 2022 of $0.19 per Class A ordinary share. The dividend will be paid on December 15, 2022, to shareholders of record at the close of business on November 18, 2022.
Royalty Pharma enters schizophrenia R&D funding collaboration with Merck
On October 12, 2022, Royalty Pharma $RPRX entered into an agreement with Merck (MRK) to co-fund the development of MK-8189, an investigational oral PDE10A inhibitor currently being evaluated in a Phase 2b study for the treatment of schizophrenia. Royalty Pharma will provide $50 million upfront to Merck to support ongoing development of MK-8189. Following Merck’s decision to proceed with Phase 3, Royalty Pharma has the option to provide an additional $375 million to co-fund the pivotal clinical development program. Royalty Pharma will be eligible for milestone payments associated with certain regulatory approvals for MK-8189 as well as royalties on annual worldwide salesThe income statement provides a summary of a company's revenue and expenses over a specified period of time, typically a year or a quarter. It shows the company's total revenue, th... of any approved product.
Jim Cramer: Newly public Royalty Pharma is a great way to play biotech
Royalty Pharma $RPRX Stock Technical Analysis
Royalty Pharma $RPRX stock is in a technical uptrend. Long-term indicators suggest a continuation of the uptrend. Short-term indicators suggest the Royalty Pharma stock is approaching overbought territory, so profit taking or a trend reversal is possible. The stock has formed a downtrend channelUptrend and downtrend channel patterns are technical analysis tools used to identify potential future price movements. They are formed by two parallel lines on a chart and can be u... breakout pattern on the chart.
